Delgocitinib: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: December 9, 2025🚩 Report this page

Delgocitinib

Agents For Dermatitis, Excluding Corticosteroids

Sold as Anzupgo

EU EMAGB MHRACA Health Canada

Drug class: Agents For Dermatitis, Excluding Corticosteroids
Availability: See label
Routes: Topical
Markets covered: 3
Products on record: 3

D11AHAgents For Dermatitis, Excluding Corticosteroids

Overview

Delgocitinib is an active pharmaceutical ingredient in the Agents For Dermatitis, Excluding Corticosteroids group (D11AH). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
EU European Union	EMA	1	December 9, 2025
GB United Kingdom	MHRA	1	November 28, 2025
CA Canada	Health Canada	1	November 6, 2025

EUEuropean Union· EMA

1 product

Uses

EUOfficial regulatory label· revised December 9, 2025[1]

1).

How to take

EUOfficial regulatory label· revised December 9, 2025

GBUnited Kingdom· MHRA

1 product

Uses

GBOfficial regulatory label· revised November 28, 2025[2]

1).

How to take

GBOfficial regulatory label· revised November 28, 2025

CACanada· Health Canada

1 product

1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].

Brands in Canada (1)

ANZUPGOLEO PHARMA INC

Sources & citations

[1]European Medicines Agency · EMEA/H/C/006109 · revised December 9, 2025
[2]MHRA (UK) · PLGB052930191 · revised November 28, 2025
[3]Health Canada (DPD) · 02560704 · revised November 6, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised November 28, 2025[2]

0%). Tabulated list of adverse reactions Table 1 lists the adverse reactions that were observed in clinical studies. The adverse reactions are presented by MedDRA system organ class and frequency, using the following categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100); rare (≥ 1/10 000 to < 1/1 000); very rare (< 1/10 000).
0% of patients treated with delgocitinib cream. 8 application site reactions were mild in severity and 1 was moderate. 7 of 9 occurred within the first week of treatment. No application site reactions resulted in treatment interruption, and the median time to resolution was 3 days.
11 events per 100 patient years of observation). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised November 28, 2025[2]

Non-melanoma skin cancer Non-melanoma skin cancer (NMSC), predominantly basal cell carcinoma, has been reported in patients treated with topical JAK inhibitors. Periodic skin examination of the application site is recommended for all patients, particularly those with risk factors for skin cancer.
Excipients with known effect Benzyl alcohol This medicinal product contains 10 mg benzyl alcohol (E 1519) in each gram of cream. Benzyl alcohol may cause allergic reactions or mild local irritation. g. contact dermatitis), or irritation to the eyes and mucous membranes.
g. contact dermatitis). Fire hazard Instruct patients not to smoke or go near naked flames – risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard.
Washing clothing and bedding may reduce product build-up but not totally remove it.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

EUEuropean Union· EMA

GBUnited Kingdom· MHRA

CACanada· Health Canada

Drugs in the same class

Sources & citations